peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

neuropeptide

DSIP

Published evidence · coverage incomplete

Anatomy in the research

Explore the structures studied.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

Brain · 1 cited passage(s)

Population: Population not specified in the source claim.

Incubation of DSIP with rat brain membrane resulted in the degradation of DSIP with liberation of tryptophan, an N-terminal amino acid of DSIP.

Applies only to the source-defined population, formulation, dose, and assessment period.

Evidence relationship: supports

Read finding and source →

At a glance

What is it—and why does it matter?

Delta sleep-inducing peptide (DSIP) is defined here by the amino-acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. The investigation is described as double-blind and cross-over, with extensive psychophysiologic observations and measurements. In this study, DSIP was associated with a 59% increase in median total sleep time during the 130-min interval after treatment compared with placebo. In cultured human intestinal epithelial (Caco-2) monolayers, apical exposure to DSIP led to extensive metabolism over 2 hr, yielding tryptophan (Trp) predominantly and Trp-Ala to a lesser extent.

Sources for this introduction: [1] [2] [3] [4]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

The peptide later named DSIP was isolated from extracorporeal dialysate of cerebral venous blood in rabbits undergoing hypnogenic electrical stimulation of the intralaminar thalamic region, and was described as inducing slow-wave EEG after intraventricular infusion.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    A peptide which induces slow-wave EEG (sleep) after intraventricular infusion into the brain has been isolated from the extracorporeal dialysate of cerebral venous blood in rabbits submitted to hypnogenic electrical stimulation of the intralaminar thalamic area.

    The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. · Abstract

    pubmed:568769:626035fc39e6:626035fc39e6

Identity

DSIP (delta sleep-inducing peptide) is described as an isolated peptide whose characterized activity includes enhancing delta sleep in rabbits.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Delta sleep-inducing peptide (DSIP) has been isolated and characterized by its capacity to enhance delta sleep in rabbits.

    Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. · Abstract

    pubmed:3029331:19f0ff227b8d:19f0ff227b8d

Identity

Historically, DSIP was proposed as a candidate endogenous factor that could promote sleep.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    and initially regarded as a candidate sleep-promoting factor.

    Delta sleep-inducing peptide (DSIP): a still unresolved riddle. · Abstract

    pubmed:16539679:92ffc612a115:92ffc612a115

Identity

Amino-acid analysis and sequencing identified DSIP as the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    It was shown by amino-acid analysis and sequence determination to be Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and named "Delta Sleep-Inducing Peptide" (DSIP).

    The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. · Abstract

    pubmed:568769:626035fc39e6:626035fc39e6

Identity

In animal experiments, delta-sleep-inducing-peptide (DSIP) was characterized as a neuropeptide.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Animal experiments confirmed the neuropeptide nature of delta-sleep-inducing-peptide (DSIP) and a species-specific sleep promotion.

    Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. · Abstract

    pubmed:6689058:eee79228edfb:eee79228edfb

Identity

DSIP is reported to have been first isolated (1977) from rabbit cerebral venous blood by the Schoenenberger-Monnier group in Basel.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Delta sleep-inducing peptide (DSIP) was isolated from rabbit cerebral venous blood by Schoenenberger-Monnier group from Basel in 1977

    Delta sleep-inducing peptide (DSIP): a still unresolved riddle. · Abstract

    pubmed:16539679:92ffc612a115:92ffc612a115

Identity

DSIP is identified in this report as a synthetic “delta sleep-inducing peptide.”

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    DSIP (= synthetic delta sleep-inducing peptide)

    Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. · Abstract

    pubmed:6895513:be3f5f898415:be3f5f898415

Identity

The peptide referred to as Delta-Sleep-Inducing Peptide is denoted by the abbreviation DSIP.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Delta-Sleep-Inducing Peptide (DSIP)

    DSIP--a tool for investigating the sleep onset mechanism: a review. · Abstract

    pubmed:3286557:69c888c3254c:69c888c3254c

Identity

Delta sleep-inducing peptide (DSIP) is defined here by the amino-acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    A cultured human intestinal epithelial (Caco-2) cell monolayer was used to study the transport and metabolism of delta sleep-inducing peptide [DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)].

    Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. · Abstract

    pubmed:8689946:2628738eee26:2628738eee26

Identity

Beyond synthesizing DSIP, the authors also synthesized five possible metabolic products, two nonapeptide analogues (with one or two amino acids exchanged), and the related tripeptide Trp-Ser-Glu.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    This compound was synthesized as well as 5 possible metabolic products (1--8, 2--9, 2--8, 1--4 and 5--9), 2 nonapeptide analogues (with one and two amino-acids exchanged) and a related tripeptide (Trp-Ser-Glu).

    The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. · Abstract

    pubmed:568769:626035fc39e6:626035fc39e6

How does it work?

Target, response, and disposition.

Mechanism

The study quantified EEG signals from frontal neocortex and limbic archicortex via direct FFT processed on an 1108 computer system.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The EEG from the frontal neocortex and the limbic archicortex were subjected to direct fast-Fourier transformation and analyzed by an 1108 computer system.

    The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. · Abstract

    pubmed:568769:626035fc39e6:626035fc39e6

Mechanism

The source notes proposed mechanisms for DSIP but states that convincing evidence supporting any proposed mechanism is lacking.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Several mechanisms of action have been proposed, though no convincing evidence for any of them has been obtained so far.

    Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. · Abstract

    pubmed:3029331:19f0ff227b8d:19f0ff227b8d

Mechanism

When DSIP was incubated with rat brain membrane, it underwent proteolytic degradation that liberated tryptophan, identified here as DSIP’s N-terminal amino acid.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Incubation of DSIP with rat brain membrane resulted in the degradation of DSIP with liberation of tryptophan, an N-terminal amino acid of DSIP.

    Characterization of the release and metabolism of delta sleep-inducing peptide (DSIP) in the rat brain. · Abstract

    pubmed:8474631:befeb0b0ea26:befeb0b0ea26

Mechanism

The investigation is described as double-blind and cross-over, with extensive psychophysiologic observations and measurements.

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    under extensive psychophysiologic observations and measurements in a double-blind cross-over design.

    Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. · Abstract

    pubmed:6895513:be3f5f898415:be3f5f898415

Pharmacokinetics

In Caco-2 monolayers, basolateral DSIP exposure showed greater peptide stability over 2 hr while producing the same metabolite profile reported for apical exposure.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    When DSIP was added to the basolateral (BL) side of the monolayer, the same metabolites were detected, but the peptide was more stable (70.6 +/- 3.0% remaining after a 2-hr incubation).

    Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. · Abstract

    pubmed:8689946:2628738eee26:2628738eee26

Pharmacokinetics

In cultured human intestinal epithelial (Caco-2) monolayers, apical exposure to DSIP led to extensive metabolism over 2 hr, yielding tryptophan (Trp) predominantly and Trp-Ala to a lesser extent.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    When applied to the apical (AP) side of Caco-2 cell monolayers, DSIP was rapidly metabolized (8.2 +/- 1.1% remaining after a 2-hr incubation), affording Trp as the major metabolite and Trp-Ala as a minor metabolite.

    Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. · Abstract

    pubmed:8689946:2628738eee26:2628738eee26

What has been studied?

What the evidence says.

Study findings

Under in vitro conditions, DSIP (20–300 nM) significantly potentiated norepinephrine-induced NAT activity at 10(-6) M norepinephrine.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    DSIP in the range between 20 and 300 nM significantly enhanced NAT activity induced by 10(-6) M norepinephrine in vitro,

    Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. · Abstract

    pubmed:3029331:19f0ff227b8d:19f0ff227b8d

Study findings

Polysomnography-based (objective) sleep outcomes suggested higher sleep efficiency in the DSIP group than in the placebo group.

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The results for objective sleep quality indicated higher sleep efficiency and shorter sleep latency with DSIP as compared to placebo.

    Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. · Abstract

    pubmed:1299794:4ad4c432640c:4ad4c432640c

Study findings

In rat pineal tissue, DSIP is reported to reduce the nocturnal rise in N-acetyltransferase (NAT) activity, with the magnitude depending on dose.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    We recently detected that DSIP reduced the nocturnal increase of N-acetyltransferase (NAT) activity in rat pineal in a dose-dependent manner.

    Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. · Abstract

    pubmed:3029331:19f0ff227b8d:19f0ff227b8d

Study findings

In this study, DSIP was associated with a 59% increase in median total sleep time during the 130-min interval after treatment compared with placebo.

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    sleep increased by 59% (median of total sleep time) within a 130-min interval after the treatment as compared with placebo.

    Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. · Abstract

    pubmed:6895513:be3f5f898415:be3f5f898415

Study findings

DSIP is reported to predominantly induce delta-sleep across rabbits, rats, mice, and humans.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    and to induce mainly delta-sleep in rabbits, rats, mice, and humans

    Delta-sleep-inducing peptide (DSIP): a review. · Abstract

    pubmed:6145137:b573feb6a21b:b573feb6a21b

Study findings

In a rabbit model, intraventricular DSIP was reported to specifically enhance EEG delta and spindle activity.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    A highly specific delta and spindle EEG-enhancing effect of the synthetic DSIP could be demonstrated.

    The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. · Abstract

    pubmed:568769:626035fc39e6:626035fc39e6

Study findings

Compared with control conditions (CSF-like solution or other tested peptides), DSIP increased cortical EEG delta power by a mean of 35% in rabbits.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The mean increase of EEG delta activity reached 35% in the neocortex and limbic cortex as compared to control animals receiving CSF-like solution or any of the other 8 peptides.

    The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. · Abstract

    pubmed:568769:626035fc39e6:626035fc39e6

Study findings

An acute subjective effect reported was an immediate feeling of sleep pressure following DSIP treatment.

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The subjects immediately reported a feeling of sleep pressure,

    Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. · Abstract

    pubmed:6895513:be3f5f898415:be3f5f898415

Study findings

In an open-label DSIP study in severe insomnia, investigators reported improvements in daytime mood and daytime performance.

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The mood and performance during the daytime improved as well.

    A clinical trial with DSIP. · Abstract

    pubmed:6391926:cad58528fdbb:cad58528fdbb

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Additional research & classification gaps

3 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.

Inspect contextual research (3)
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Despite being studied, DSIP’s endogenous presence and its biological activities are described as not well understood.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Beyond sleep-related activity, DSIP is described as producing multiple physiological effects.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

According to the authors, evidence connecting DSIP to sleep remains insufficiently characterized, making the sleep-factor hypothesis poorly documented and weak.

Research context only—not evidence of a treatment effect.

  • Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
    However, the link between DSIP and sleep has never been further characterized, in part because of the lack of isolation of the DSIP gene, protein and possible related receptor. Thus the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
  • 77 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (56), assurance_score_below_0.72 (12), current_regulatory_source_required (14), extraction_ambiguity (65), high_risk_requires_regulatory_or_two_independent_sources (21), no_direct_support (64)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

    pubmed · published 1992-01-01 · retrieved 2026-09-08T21:48:22Z

  2. Delta sleep-inducing peptide (DSIP): a still unresolved riddle.

    pubmed · published 2006-04-01 · retrieved 2026-09-04T19:33:14Z

  3. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor.

    pubmed · published 1987-04-01 · retrieved 2026-09-09T18:02:12Z

  4. DSIP--a tool for investigating the sleep onset mechanism: a review.

    pubmed · published 1988-02-01 · retrieved 2026-09-09T21:43:29Z

  5. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide.

    pubmed · published 1978-09-06 · retrieved 2026-09-08T21:48:23Z

  6. Delta-sleep-inducing peptide (DSIP): a review.

    pubmed · published 1984-01-01 · retrieved 2026-09-09T21:43:28Z

  7. A clinical trial with DSIP.

    pubmed · published 1984-01-01 · retrieved 2026-09-04T19:33:15Z

  8. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.

    pubmed · published 1983-01-01 · retrieved 2026-09-09T18:02:12Z

  9. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.

    pubmed · published 1981-08-01 · retrieved 2026-09-04T19:33:13Z

  10. Characterization of the release and metabolism of delta sleep-inducing peptide (DSIP) in the rat brain.

    pubmed · published 1993-03-01 · retrieved 2026-09-09T21:43:31Z

  11. Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers.

    pubmed · published 1995-12-01 · retrieved 2026-09-09T18:02:13Z

Publication history and provenance

Version 2 · Automated assessment · 2026-09-09T21:43:31Z

e52725f17c42a132571ffdc08071591584a3c6ddafb5c78651a20218b22400ff